MP42-08 THE CHANGING TRENDS OF IMAGE GUIDED BIOPSY OF SMALL RENAL MASSES BEFORE INTERVENTION- AN ANALYSIS OF EUROPEAN MULTINATIONAL PROSPECTIVE EuRECA REGISTRY

Abstract

You have accessJournal of UrologyKidney Cancer: Localized: Surgical Therapy III (MP42)1 Sep 2021MP42-08 THE CHANGING TRENDS OF IMAGE GUIDED BIOPSY OF SMALL RENAL MASSES BEFORE INTERVENTION- AN ANALYSIS OF EUROPEAN MULTINATIONAL PROSPECTIVE EuRECA REGISTRY Vinson Wai-Shun Chan, Francis Keeley, Brunolf Lagerveld, Tommy Nielsen, Patricia Zondervan, Giovanni Lughezzani, and Tze Min Wah Vinson Wai-Shun ChanVinson Wai-Shun Chan More articles by this author , Francis KeeleyFrancis Keeley More articles by this author , Brunolf LagerveldBrunolf Lagerveld More articles by this author , Tommy NielsenTommy Nielsen More articles by this author , Patricia ZondervanPatricia Zondervan More articles by this author , Giovanni LughezzaniGiovanni Lughezzani More articles by this author , and Tze Min WahTze Min Wah More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002063.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Performing image-guided biopsy of incidental small renal masses (SRMs) pre-treatment to minimise overtreatment of benign renal masses is advocated. This study aims to assess the trends and potential factors influencing the decision to perform image-guided biopsy before cryoablation treatment. METHODS: From December 2014 to October 2020, patients with T1N0M0 SRMs undergoing percutaneous cryoablation from 14 European institutions within the European Registry For Renal Cryoablation (EuRECA) were included for the retrospective analysis. The trends of performing image-guided biopsy as a separate session before cryoablation of SRMs were analysed over time, and the potential factors influencing the decision to perform image-guided biopsy before treatment were analysed using multivariate logistic regression model. RESULTS: 1,050 patients were evaluated. The use of pre-cryoablation biopsy has significantly increased from 39% (67/171) in 2015 to 72% (88/122) in 2019 (p <0.001; figure 1). Rates of undiagnosed histology and benign histology is significantly higher in patients undergoing biopsy at the time of treatment (16% [50/313] vs 0.16% [1/636], p <0.001; Figure 2). For every 4.5 patients receiving pre-cryoablation biopsy, one less patient receives cryoablation treatment for a non-malignant renal tumor. Aged 70-79 (OR 0.53, 95% CI 0.29-0.96), 80-89 (OR 0.47, 95% CI 0.24-0.92), obesity (OR 0.73, 95% CI 0.55-0.98) and having a solitary kidney (OR 0.40, 95% CI 0.27-0.61) are three patients’ factors associated with less likelihood of pre-cryoablation biopsy (p <0.05). R.E.N.A.L. nephrometry score of 10+ (OR 1.86, 95% CI 1.11-3.10) and a Charlson Comorbidity Index >1 (OR 2.11, 95% CI 1.54-2.88) are factors associated with higher likelihood to have received a pre-cryoablation biopsy (p <0.05). CONCLUSIONS: Pre-cryoablation biopsy should be advocated as it is more likely to lead to confirmatory histological diagnosis than biopsy at the time of cryoablation, thus reducing overtreatment of non-malignant SRMs. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e774-e774 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Vinson Wai-Shun Chan More articles by this author Francis Keeley More articles by this author Brunolf Lagerveld More articles by this author Tommy Nielsen More articles by this author Patricia Zondervan More articles by this author Giovanni Lughezzani More articles by this author Tze Min Wah More articles by this author Expand All Advertisement Loading ...